CN113599376A - Application of tectorigenin A in preparing medicament for preventing and treating bronchial asthma - Google Patents
Application of tectorigenin A in preparing medicament for preventing and treating bronchial asthma Download PDFInfo
- Publication number
- CN113599376A CN113599376A CN202110848306.2A CN202110848306A CN113599376A CN 113599376 A CN113599376 A CN 113599376A CN 202110848306 A CN202110848306 A CN 202110848306A CN 113599376 A CN113599376 A CN 113599376A
- Authority
- CN
- China
- Prior art keywords
- tectorigenin
- group
- bronchial asthma
- ova
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the technical field of tectorigenin A, and relates to an application of tectorigenin A in preparing a medicament for preventing and treating bronchial asthma. The invention discloses application of tectorigenin A in preparing a medicament for preventing and treating bronchial asthma for the first time, wherein the tectorigenin A not only can effectively reduce lung airway resistance of a model mouse and improve airway hyperresponsiveness of the model mouse, but also can reduce the number of total leukocytes, monocytes and basophilic granulocytes in alveolar lavage fluid of the model mouse and effectively control inflammation, and meanwhile, airway inflammatory factors IL-4 and IL-5 can be remarkably reduced, so that the effective treatment of bronchial asthma is realized.
Description
Technical Field
The invention relates to the technical field of tectorigenin A, and relates to an application of tectorigenin A in preparing a medicament for preventing and treating bronchial asthma.
Background
Bronchial asthma belongs to inflammation-related diseases and seriously threatens physical and psychological health of people. Local inflammatory hyperactivity, immune disorders and airway hyperreactivity are the main pathological features. Anti-inflammatory treatment of asthma is generally the main therapeutic principle, and glucocorticoids are important therapeutic approaches. However, long-term use of the drugs can cause drug resistance of the drugs, and the life quality of patients is seriously affected in the later period.
Disclosure of Invention
The invention provides an application of tectorigenin A in preparing a medicament for preventing and treating bronchial asthma, overcomes the defects of the prior art, and discloses an application of tectorigenin A in preparing a medicament for preventing and treating bronchial asthma for the first time, thereby realizing the effective treatment of bronchial asthma.
One of the technical schemes of the invention is realized by the following measures: an application of tectorigenin A in preparing medicine for preventing and treating bronchial asthma is disclosed.
The following is further optimization or/and improvement of the technical scheme of the invention:
the tectorigenin A is extracted from rhizoma Belamcandae.
The medicine is obtained by loading tectorigenin A in any pharmaceutically acceptable dosage form.
The pharmaceutically acceptable dosage form is prepared by pharmaceutically allowable and pharmaceutically acceptable auxiliary materials.
The pharmaceutically acceptable dosage form is one of tablets, granules, capsules and oral liquid.
The invention discloses application of tectorigenin A in preparing a medicament for preventing and treating bronchial asthma for the first time, wherein the tectorigenin A not only can effectively reduce lung airway resistance of a model mouse and improve airway hyperresponsiveness of the model mouse, but also can reduce the number of total leukocytes, monocytes and basophilic granulocytes in alveolar lavage fluid of the model mouse and effectively control inflammation, and meanwhile, airway inflammatory factors IL-4 and IL-5 can be remarkably reduced, so that the effective treatment of bronchial asthma is realized.
Drawings
FIG. 1 is a line graph showing the variation of airway Resistance (RL) for each group of the present invention.
FIG. 2 is a bar graph of the change in total White Blood Cells (WBC) in each group of alveolar lavage fluid (BALF) of the present invention.
FIG. 3 is a bar graph showing the change in monocytes in groups of alveolar lavage fluid (BALF) according to the present invention.
FIG. 4 is a bar graph showing the change in basophils (Basophils) in each group of alveolar lavage fluid (BALF) of the present invention.
FIG. 5 is a scattergram showing the changes in interleukin 4 (IL-4) in the supernatant of alveolar lavage fluid (BALF) of mice in each group of mice in the present invention.
FIG. 6 is a scattergram showing the changes in interleukin 5 (IL-5) in the supernatant of alveolar lavage fluid (BALF) of mice in each group of mice in the present invention.
Detailed Description
The present invention is not limited by the following examples, and specific embodiments may be determined according to the technical solutions and practical situations of the present invention. The various chemical reagents and chemical articles mentioned in the invention are all the chemical reagents and chemical articles which are well known and commonly used in the prior art, unless otherwise specified; the percentages in the invention are mass percentages unless otherwise specified; the solution in the present invention is an aqueous solution of water as a solvent, for example, a hydrochloric acid solution is an aqueous hydrochloric acid solution, unless otherwise specified.
The invention is further described below with reference to the following examples:
example 1: an application of tectorigenin A in preparing medicine for preventing and treating bronchial asthma is disclosed.
Example 2: as optimization of the embodiment, tectorigenin A is extracted from rhizoma Belamcandae.
Example 3: as an optimization of the above examples, the drug was loaded with tectorigenin A in any pharmaceutically acceptable dosage form.
Example 4: as an optimization of the above embodiment, the pharmaceutically acceptable dosage form is one of a tablet, a granule, a capsule and an oral liquid.
And (5) pharmacodynamic experiments. Experimental animals: adopting healthy and clean BALB/c mice, and breeding in the center of laboratory animals of college of medicine of Zaodan university, wherein the breeding conditions are as follows: the illumination time is fixed, and water and food can be freely taken.
Reagents and instrumentation: egg proteins (Shanghai Lizhuofeng Biotechnology Co., Ltd.); aluminum hydroxide gel (Sigma company, usa); pentobarbital sodium (imported from Shanghai chemical reagent company for split charging); IL-4 and IL-5 kits (import Split Biosource Biotech); DL-8R refrigerated centrifuge (Shanghai centrifugal mechanical research institute); model YS9801 medical ultrasonic nebulizer (shanghai yi sheng science ltd); animal asthma inducing device: incompletely seal the organic glass box, (28X 15X 13) cm3, wherein one end of the box body is provided with a vent hole, and the other end of the box body is connected with an ultrasonic atomizer.
Grouping: 50 female BALB/c mice with the healthy cleanliness grade of 6-8 weeks old, 16-18 g in body weight, and randomly divided into 5 groups, namely a normal control group (hereinafter referred to as NC group), an asthma model group (hereinafter referred to as OVA/Saline group), a dexamethasone dry-control group (hereinafter referred to as OVA/Dex group), an tectorigenin A low-dose (5mg/kg) dry-control group (hereinafter referred to as OVA/ITG 5 group) and an tectorigenin A high-dose (10mg/kg) dry-control group (hereinafter referred to as OVA/ITG 10 group).
Establishing an asthma model: the mice are injected with 0.2ml of physiological saline suspension of 20ug egg protein and 2mg aluminum hydroxide in the abdominal cavity once from day 1, so that the mice are in a sensitized state, 1 time per week and 4 times of sensitization. Inhalation of 3% egg protein was nebulized on day 27, each for about 30 minutes to induce asthma, and nebulization was continued for 7 days. The mice have the symptoms of accelerated respiration, abdominal muscle spasm, cyanosis of lips, noded head respiration, unstable standing and the like, and the successful establishment of the model is shown.
Administration: gavage administration was started on day 8 after sensitization in OVA/ITG 5 group and OVA/ITG 10 group, respectively, and before tectorigenin A was used, gavage was performed after forming a suspension with sodium carboxymethylcellulose, and gavage administration was performed in two groups, respectively, by administering 0.2ml of a suspension formed with a low tectorigenin A dose (5mg/kg) and a suspension formed with a high tectorigenin A dose (10mg/kg), 1 time per day, for 7 days continuously, administering dexamethasone (1 mg/kg) in OVA/Dex group, and administering physiological Saline in an equal amount in NC group and OVA/Saline group for 7 days continuously.
Test 1: examination of lung function in each group. The test method comprises the following steps: the lung function measurement is carried out by selecting an invasive detection system of Buxco company airway resistance and lung compliance, and the detection of airway Resistance (RL) refers to a method established by Picovant M and the like. The specific steps for the treatment of each group of rats were as follows: 1. pentobarbital sodium (50 mg/kg) is administered for anesthesia; 2. performing tracheal intubation: fixing anesthetized BALB/c mouse on operation board, preparing neck skin, sterilizing, cutting neck skin, peeling muscle layer by layer, performing sexual separation, exposing trachea, cutting a T-shaped small incision (at the 4 th and 5 th cricoid cartilages) on the separated neck trachea, and performing tracheal intubation; 3. placing the mouse into a plethysmograph box, and performing respiratory assisted ventilation; 4. measuring the baseline pulmonary resistance of the mouse, keeping the mouse stable and keeping the variation rate less than 5%, and recording for 3 min; 5. followed by nebulization with increasing concentrations of acetylcholine ranging from low to high at 3.125mg/ml, 12.5mg/ml and 50 mg/ml. Each atomization was 10s, recorded for 3min, with 4min intervals. The acetylcholine enters the animal airway along with the air flow of the breathing machine after passing through the atomizer, and the reactivity of the mouse airway is reflected by measuring the airway Resistance (RL) after excitation.
As a result: the trend of the airway Resistance (RL) changes, as shown in figure 1, wherein the abscissa is the concentration of acetylcholine, and the ordinate is the growth rate of the airway resistance, and as known from figure 1, the lung airway resistance of mice in the OVA/Saline group is remarkably increased compared with that in the NC group, which indicates that the OVA/Saline group has remarkable airway hyperreactivity, and the model preparation is proved to be successful. After the model mice are subjected to administration drying, when the concentration of the atomized inhaled acetylcholine is 3.125mg/ml and 12.5mg/ml, the lung airway Resistance (RL) of the mice is not reduced in each group, when the concentration of the atomized inhaled acetylcholine is 50mg/ml, the lung airway Resistance (RL) of the mice is remarkably reduced in all the OVA/Dex group, the OVA/ITG 5 group and the OVA/ITG 10 group compared with the OVA/Saline group, and the drug effect of the OVA/ITG 5 group is more remarkable than that of the OVA/ITG 10 group.
Test 2: examination of the number of leukocytes in alveolar lavage fluid (BALF) of mice in each group. The test method comprises the following steps: after blood is collected from a mouse, the mouse is fixed on an operation plate, a specially-made blunt needle is inserted into the exposed neck trachea, the needle head and the trachea are fixedly ligated together, and the thoracic cavity is opened to ligate the right main bronchus. The trachea was slowly injected with 0.5ml of pre-cooled PBS buffer containing 3% BSA using a 1ml syringe, and the lavage fluid was rapidly withdrawn to perform left lung lavage, and the injection and withdrawal were repeated 2 times. The recovered liquid was centrifuged at 1200rpm at 4 ℃ for 10 min. Taking the supernatant, transferring into a sterile centrifugal tube, and storing in a refrigerator at-80 deg.C. After the precipitated cells were resuspended in 0.2ml of PBS buffer containing 3% BSA, the precipitated cells were stained with Ruhry or Giemsa, and total leukocytes (WBC), monocytes (Monocytes) and basophils (Basophil) in alveolar lavage fluid (BALF) were sorted and counted using a hemocytometer.
As a result: the number of total leukocytes in alveolar lavage fluid (BALF) of each group varied, as shown in FIG. 2, and as seen from FIG. 2, the total leukocytes were significantly increased in the OVA/Saline group (P < 0.001), significantly decreased in the OVA/ITG 5 group and OVA/Dex group (P < 0.01), and had no effect on the total leukocytes in the ITG 10 group, compared to the NC group; the number of monocytes varied in each alveolar lavage fluid (BALF) group, as shown in FIG. 3, and as is clear from FIG. 3, the number of monocytes was significantly increased in the OVA/Saline group (P < 0.001) as compared with the NC group, and significantly decreased in all of the OVA/Dex group, OVA/ITG 5 group and OVA/ITG 10 group (P < 0.01) as compared with the OVA/Saline group; as shown in FIG. 4, the number of basophils in the alveolar lavage fluid (BALF) of each group was significantly increased (P < 0.001) compared with that of NC group, and the number of basophils was significantly decreased (P < 0.01) in OVA/Saline group compared with that of NC group, whereas there was no significant difference between OVA/ITG 10 group and OVA/Dex group in OVA/ITG 5 group, indicating that the low dose (5mg/kg) of tectorigenin A administered to model mice was effective in decreasing the number of total leukocytes (WBC), monocytes (Monocyte) and basophils (Basophil) in the alveolar lavage fluid (BALF) of model mice and controlling inflammation.
Test 3: investigation of Interleukin 4 (IL-4) and Interleukin 5 (IL-5) in the alveolar lavage (BALF) supernatants of mice in each group. The test method comprises the following steps: the level of interleukin 4 (IL-4) and interleukin 5 (IL-5) in alveolar lavage fluid (BALF) of each group of mice was measured by ELISA.
As a result: the change of interleukin 4 (IL-4), as shown in fig. 5, was observed from fig. 5 that the expression level of interleukin 4 (IL-4) in the supernatant of alveolar lavage fluid (BALF) of mice in OVA/salt group was significantly increased (P < 0.001) as compared to NC group, and the expression level of interleukin 4 (IL-4) in the supernatant of alveolar lavage fluid (BALF) of mice in OVA/Dex group, OVA/ITG 5 group and OVA/ITG 10 group was significantly decreased (P < 0.01) as compared to OVA/salt group, wherein the expression level of interleukin 4 (IL-4) was significantly decreased in OVA/ITG 5 group; as shown in FIG. 6, it is seen from FIG. 6 that the expression level of interleukin 5 (IL-5) in the supernatant of alveolar lavage fluid (BALF) of mice in the OVA/Saline group was significantly increased (P < 0.001) as compared with that in the NC group, and the expression level of interleukin 5 (IL-5) in the supernatant of alveolar lavage fluid (BALF) of mice in the OVA/Dex group, OVA/ITG 5 group and OVA/ITG 10 group was significantly decreased (P < 0.001) as compared with that in the OVA/Saline group, wherein the expression levels of interleukin 5 (IL-5) were significantly decreased in the OVA/ITG 5 group and OVA/ITG 10 group, and the expression levels of interleukin 4 (IL-4) and interleukin 5 (IL-5) in the OVA/Saline group were significantly decreased in the OVA/Saline group.
In conclusion, the invention discloses the application of tectorigenin A in preparing the medicament for preventing and treating bronchial asthma for the first time, the tectorigenin A not only can effectively reduce the lung airway resistance of a model mouse and improve the airway hyperresponsiveness of the model mouse, but also can reduce the number of total leukocytes, monocytes and basophilic granulocytes in alveolar lavage fluid of the model mouse and effectively control inflammation, and meanwhile, the airway inflammatory factors IL-4 and IL-5 can be obviously reduced, thereby realizing the effective treatment of the bronchial asthma.
The technical characteristics form an embodiment of the invention, which has strong adaptability and implementation effect, and unnecessary technical characteristics can be increased or decreased according to actual needs to meet the requirements of different situations.
Claims (5)
1. An application of tectorigenin A in preparing medicine for preventing and treating bronchial asthma is disclosed.
2. The use of tectorigenin a in the manufacture of a medicament for the prevention or treatment of bronchial asthma, as claimed in claim 1, wherein tectorigenin a is extracted from belamcanda chinensis, a Chinese medicinal material.
3. The use of tectorigenin a in the manufacture of a medicament for the treatment or prophylaxis of bronchial asthma as claimed in claim 1 or 2, characterized in that the medicament is obtained by loading tectorigenin a in any pharmaceutically acceptable dosage form.
4. The use of tectorigenin a in the manufacture of a medicament for the prevention or treatment of bronchial asthma as claimed in claim 3, characterised in that the pharmaceutically acceptable dosage form is formulated with pharmaceutically acceptable and pharmaceutically acceptable excipients.
5. The use of tectorigenin a in the manufacture of a medicament for the treatment or prophylaxis of bronchial asthma as claimed in claim 4, wherein the pharmaceutically acceptable dosage form is one of a tablet, a granule, a capsule and an oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110848306.2A CN113599376A (en) | 2021-07-27 | 2021-07-27 | Application of tectorigenin A in preparing medicament for preventing and treating bronchial asthma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110848306.2A CN113599376A (en) | 2021-07-27 | 2021-07-27 | Application of tectorigenin A in preparing medicament for preventing and treating bronchial asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113599376A true CN113599376A (en) | 2021-11-05 |
Family
ID=78305533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110848306.2A Pending CN113599376A (en) | 2021-07-27 | 2021-07-27 | Application of tectorigenin A in preparing medicament for preventing and treating bronchial asthma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113599376A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106963853A (en) * | 2017-04-11 | 2017-07-21 | 四川省中医药科学院 | A kind of Rhizoma Belamcandae total-flavonoid aglycone extract and its production and use |
| CN106995425A (en) * | 2017-04-20 | 2017-08-01 | 四川省中医药科学院 | The extraction process and its isolation and purification method of a kind of Rhizoma Belamcandae flavone aglycone |
-
2021
- 2021-07-27 CN CN202110848306.2A patent/CN113599376A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106963853A (en) * | 2017-04-11 | 2017-07-21 | 四川省中医药科学院 | A kind of Rhizoma Belamcandae total-flavonoid aglycone extract and its production and use |
| CN106995425A (en) * | 2017-04-20 | 2017-08-01 | 四川省中医药科学院 | The extraction process and its isolation and purification method of a kind of Rhizoma Belamcandae flavone aglycone |
Non-Patent Citations (1)
| Title |
|---|
| 郑文江: "《基于网络药理学的射干-麻黄药对治疗支气管哮喘的分子机制探讨》", 《中国实验方剂学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS634812B2 (en) | ||
| CN109999052B (en) | Use of beta-nicotinamide mononucleotide or a precursor thereof for the manufacture of a medicament for the treatment or alleviation of a respiratory disorder or disease | |
| CN112546046B (en) | Application of arbidol hydrochloride in preparation of medicine for treating pulmonary fibrosis diseases | |
| CN111329870B (en) | Application of Yadanzigan in preparing medicine for treating and/or preventing lung injury | |
| CN111265535B (en) | Application of pulsatilla chinensis saponin B4 in preparation of medicines for treating/preventing pulmonary fibrosis | |
| CN112675179A (en) | Application of Ivitinib in preparation of medicine for treating idiopathic pulmonary fibrosis | |
| CN115427576A (en) | Composition for preventing or treating pulmonary diseases comprising hyaluronic acid and proteoglycan connexin 1 | |
| CN111249291A (en) | Application of pulsatilla saponin B4 in preparation of medicine for treating/preventing bacterial pneumonia | |
| CN113599376A (en) | Application of tectorigenin A in preparing medicament for preventing and treating bronchial asthma | |
| CN102302504A (en) | Application of high-purity baicalin or baicalein to preparation of inhaled asthma relieving medicament | |
| CN111820188B (en) | Establishment method and application of asthma-like slow obstructive pulmonary overlapping airway inflammation mouse model | |
| WO2023097706A1 (en) | Application of polymerized hemoglobin in preparation of drug for preventing and treating respiratory failure | |
| CN113908149A (en) | Application of formononetin in preparation of medicine for preventing and treating acute lung injury | |
| CN106344599B (en) | Application of triterpenoid saponin compound | |
| CN108096242B (en) | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease | |
| EA032116B1 (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
| CN110433181A (en) | Application of the hayashishita Shanxi American ginseng in preparation treatment Chronic Obstructive Pulmonary Disease drug | |
| RU2504395C1 (en) | Method for prediction of bronchopulmonary dysplasia in newborns with very low or extremely low birth body weight | |
| JP2022014868A (en) | Application of tanreqing in preparation of drug for treatment of acute exacerbation of chronic obstructive pulmonary disease | |
| CN111956655B (en) | Application of pulsatilla saponin B4 in preparation of medicine for treating chronic obstructive pulmonary disease | |
| CN113559100B (en) | Composition for treating lung injury and application thereof | |
| CN117224518B (en) | Application of sofalcone in preparation of medicine for preventing/treating allergic asthma | |
| CN111920785B (en) | Inhalation preparation of iso-glycyrrhizic acid or salt thereof and application thereof | |
| WO2008095429A1 (en) | A glycoprotein for treating chronic obstructive pulmonary diseases | |
| Wei et al. | Effect of kekeling mixture on the levels of IL-6 and IL-8 in RSV infected mice. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |